Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)

11 March 2022

Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)

The health insurer does not yet fully reimburse Jardiance (Empagliflozin)® 10 mg for the treatment of HFpEF (Ejection fraction >40%). The manufacturer of this medicine has therefore asked TBR Nederland to reimburse the total costs for the patient.

Conditions

Jardiance® (empagliflozin) 10 mg will be reimbursed by TerugBetaalRegeling when adults are diagnosed with heartfailure and have an ejection fraction >40%, when:

  • Prescription is not eligible for reimbursement by the health insurer.
  • Jardiance is prescribed by a cardiologist, nurse specialist or phycisian assistant.

Invoicing by the pharmacy or patients is possible when Jardiance is prescribed after March 3th 2022. 

Who can submit a claim

Pharmacies, patients or their caregivers can claim the costs of Jardiance (empagliflozine) 10 mg for the treatment of HFpEF (Ejection fraction >40%) online or by post. Online will be the fastest option.

More information on Jardiance® (empagliflozin) 10 mg webpage

You are currently offline. Some pages or content may fail to load.